Biocartis : Corporate Presentation

Biocartis

Corporate Presentation

7 January 2019

NOTICES AND WARNINGS

This presentation has been prepared by the management of Biocartis Group NV (the "Company"). It does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. It is not a prospectus or offering memorandum.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. No person is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, accuracy, reasonableness or completeness of the information contained herein. Neither the Company nor any other person accepts any liability for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results, condition, performance, prospects, growth, strategies and the industry in which the Company operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors that could cause the Company's actual results, condition, performance, prospects, growth or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. The Company cautions you that forward-looking statements are not guarantees of future performance and that its actual results and condition and the development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if the Company's results, condition, and growth and the development of the industry in which the Company operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. The Company and each of its directors, officers and employees expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in the Company's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This document and any materials distributed in connection with this document are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The Company's securities have not been and will not be registered under the US Securities Act of 1933 (the "Securities Act") and may not be offered or sold in the United States absent registration under the Securities Act or exemption from the registration requirement thereof.

Leader in oncology precision diagnostics

• • Idylla™: first fully automated sample-to-result qPCR platform

• • Superior and validated performance versus competition

• • Enabling global decentralization of clinical molecular diagnostics (MDx)

• • Global MDx market of USD 6.5bn; oncology fastest growing segment with high double digit annual growth rates

• • Large, global customer base & opportunity to add new customer segments, e.g. labs that want to step into MDx testing

• • Unique platform features bring strong competitive advantage in oncology testing

• • Broad test menu (solid & liquid biopsies) for therapy guidance, later for patient monitoring & screening

• • Validation via partnerships with pharma (e.g. Amgen, Merck KGaA, AstraZeneca) and content partners (e.g. Genomic Health)

• • Installed base grew to around 970 Idylla™ instruments as per 31 December 2018

• • Present in over 70 countries

• • Delivering solid performance across markets: Europe, US and RoW*

• • 326 new Idylla™ instrument placements in 2018, resulting in an installed base of around 970 Idylla™ instruments at the end of 2018

• • Commercial volume of approx. 133k cartridges in 2018, representing a year-over-year increase of approx. 87%

• • Global coverage of all major markets: successful initial roll-out of the Idylla™ platform in the US, joint venture with Wondfo for commercialization in China and distribution agreement with Nichirei Bioscience for commercialization in Japan

• • Launch of the Idylla™ MSI Assay (Research Use Only) in Q3 2018, driving cartridge volume growth at existing and new clients

• • Additional highly automated second cartridge manufacturing line to support volume growth and cost effectiveness

* RoW = Rest of the World. RoW is defined as the world excluding Europe, US, China and Japan

Difficult access to molecular diagnostics information

• • In the US, nearly 80%4 of cancer patients do not have genetic mutation results available at initial oncology consultation

• • Up to 25% of patients begin treatment before receiving their results4

Source: 1 Schwaederle et al. (2014) Oncologist 19, 631 - 636; 2 Saunders et al. ESMO 2016, Abstract #; 3 INCa 2012 Survey, 3 Etude FLASH RAS 2014; 4 JMD, May 2017; 5 Scott et al. (2014) Asia Pac J Clin Oncol. 10(3):261-5.

Cartridge (consumable)

Fully automated molecular testing with Idylla™

InstrumentelosnoC

Scan sample

Scan cartridgeLoad sampleInsert cartridge

Clinically-actionable results

Superior sensitivity and ease-of-use, combined with sample to result turnaround time of 90 to 150* minutes

* Based on turnaround times of current on-market oncology tests